The self-testing point of care coagulation market is one of the largest sectors in the global point-of-care industry. In 2011, the market was valued at $1.0bn. By 2017, the global coagulation analyzer market was valued at $1.8bn.
“Global Coagulation Analyzer Market to Surpass US$ 13.17 Billion by 2025”.
Department of Health and Social Care Reviews Facility – To support national policy development and implementation “The effective, safe and appropriate use of anticoagulation medicines.
A systematic overview of reviews” – cites 2016 Cochrane systematic review.
Roche introduces first self-testing device for Warfarin monitoring with built-in Bluetooth® technology.
“Patient self-testing with the Bluetooth-enabled CoaguChek Vantus system allows for a new level of patient monitoring. Patients can use their tablet or smartphone with a compatible app to send their results automatically via wireless connectivity which enables healthcare providers to receive patient INR results rapidly and accurately, while also reducing visits to the lab.” citing 2016 Cochrane systematic review on self-monitoring.
NOACs: good for some perhaps, but not for all
Kamal R Mahtani
Roche – “In vitro diagnostics: enabling better health decisions” cites Lancet 2012 review.
American College of Chest Physicians – Antithrombotic Therapy for Atrial Fibrillation – CHEST Guideline and Expert Panel Report – cites 2016 Cochrane review on self-monitoring.
REACH – The website of CHEST states “CHEST is the global leader in prevention, diagnosis and treatment of chest diseases. Its mission is to champion advanced clinical practice, education communication and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine.”